Effect of Midazolam upon the Prevention of Nausea and Vomiting after Middle Ear Surgery

Jung, Jae Sik; Jeon, Yongseok

doi:10.4097/kjae.2007.52.5.550

Cited by 3 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Midazolam's mechanism of action is believed to work by decreasing dopamine input at the chemoreceptor trigger zone and decreasing serotonin release at the GABA benzodiazepine complex [67]. Midazolam 2 mg IV given 30 min before the end of surgery decreased PONV more than midazolam 35 mcg/kg IV given as premedication [68].…”

Section: Midazolammentioning

confidence: 99%

Postoperative and Postdischarge Nausea and Vomiting After Ambulatory Surgery: An Update

Kovac

2014

Curr Anesthesiol Rep

View full text Add to dashboard Cite

Patients undergoing ambulatory surgery have similar, but also different nausea and vomiting stimuli and mechanisms than inpatients. As the emphasis on ''street readiness'' and discharge home is a unique and important concern for outpatients, various medications, formulations, techniques, risk scores, and guidelines have been introduced to help improve the care of patients having ambulatory surgery. Additional research and data have been obtained regarding the effects of postoperative nausea and vomiting (PONV) and postdischarge nausea and vomiting (PDNV) on ambulatory anesthesia. More effective antiemetic combination techniques and new long-acting antiemetics have been introduced for PONV and PDNV prevention. Antiemetic drug selection for ambulatory surgery depends on efficacy, cost, adverse effects, and ease of dosing. Safety concerns include adverse events such as the ECG QTc prolongation effects of antiemetics. To help guide antiemetic drug selection, techniques, and therapy, the PONV consensus guidelines were updated in 2014.

show abstract

Section: Midazolammentioning

confidence: 99%

Postoperative and Postdischarge Nausea and Vomiting After Ambulatory Surgery: An Update

Kovac

2014

Curr Anesthesiol Rep

View full text Add to dashboard Cite

show abstract

Update on the Management of Postoperative Nausea and Vomiting

Kovac

2013

Drugs

140

View full text Add to dashboard Cite

New antiemetic drug developments, formulations, guidelines, risk evaluation, and controversies have occurred in the area of postoperative nausea and vomiting (PONV). These developments have helped improve our understanding of the prevention and treatment of PONV in the postanesthesia care unit and after discharge home or to the hospital ward. Antiemetic drug research has resulted in the introduction of the second-generation 5-hydroxytryptamine-3 (5-HT3) receptor antagonist palonosetron and the neurokinin-1 (NK-1) receptor antagonist aprepitant, as well as new data on existing antiemetics. The next frontier and need for further nausea and vomiting research and therapy is the area of postdischarge nausea and vomiting after the patient is discharged home from phase II of the ambulatory stepdown unit or to the hospital ward. Antiemetic drug selection depends on efficacy, cost, safety, and ease of dosing. Safety concerns have arisen regarding the side effects of antiemetics, specifically their effect on the ECG with prolongation of the QTc interval by the butyrophenones and the first-generation 5-HT3 receptor antagonist class of antiemetics. The impact of pharmocogenetics on antiemetic drug metabolism and their resulting efficacy has been correlated with genetic makeup affecting drug response. A discussion of ethics in PONV research has been initiated by the meta-analysis of PONV studies. To help guide antiemetic selection and PONV therapy for clinical practitioners, the Society of Ambulatory Anesthesia (SAMBA) PONV consensus guidelines have been introduced and updated.

show abstract